• This graph shows the total number of publications written about "Proto-Oncogene Proteins c-abl" by people in this website by year, and whether "Proto-Oncogene Proteins c-abl" was a major or minor topic of these publications. (jefferson.edu)
  • Below are the most recent publications written about "Proto-Oncogene Proteins c-abl" by people in Profiles. (jefferson.edu)
  • JOA displayed the activity of inhibiting the BCR-ABL and promoted differentiation of not only imatinib -sensitive but also imatinib -resistant cells with BCR-ABL mutation, which could become a potent lead compound to overcome the imatinib -resistant induced by inhibitors of BCR-ABL tyrosine kinase in CML therapy. (jcancer.org)
  • For most patients with CML, BCR-ABL tyrosine kinase inhibitors (TKIs) have turned the an inevitably fatal disease into a manageable condition. (jcancer.org)
  • Cooperativity between ß-agonists and c-Abl inhibitors in regulating airway smooth muscle relaxation. (jefferson.edu)
  • Bcr-Abl fusion protein has constitutively activated Abl tyrosine kinase activity which is responsible for the uncontrolled proliferation in CML The tyrosine kinase inhibitors (TKIs) such as Imatinib, Dasatinib, and Nilotinib are the current first-line treatments approved by the United States Food and Drug Administration (US FDA) for the treatment of the disease. (eurekaselect.com)
  • This review outlines the Bcr-Abl dependent and independent mechanism of TKIs resistance development and the strategies used to overcome drug resistance, such as the development of ATP site and allosteric site inhibitors. (eurekaselect.com)
  • Kaiso and prognosis As expected for a transcriptional aspect, the Kaiso Inhibitors,Modulators,Libraries protein is often discovered while in the nucleus of quite a few tumor or non tumor derived mammalian cell lines. (screeninglibraries.com)
  • Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. (jefferson.edu)
  • Genes whose protein products stimulate or enhance the division and viability of cells. (cancerquest.org)
  • Genes whose protein products can directly or indirectly prevent cell division or lead to cell death. (cancerquest.org)
  • The abnormal BCR-ABL1 gene is made when two separate genes merge together and become one gene. (medlineplus.gov)
  • Your genes carry special instructions for making proteins that help your cells do their work. (medlineplus.gov)
  • See how well your treatment is working (if treatment is helping, the number of cells with BCR-ABL1 genes will decrease. (medlineplus.gov)
  • The multifunctional regulator nuclear factor erythroid 2-related factor (Nrf2) is considered not only as a cytoprotective factor regulating the expression of genes coding for anti-oxidant, anti-inflammatory and detoxifying proteins, but it is also a powerful modulator of species longevity. (springer.com)
  • The major characteristics of Nrf2 are to some extent mimicked by Nrf2-dependent genes and their proteins including heme oxygenase-1 (HO-1), which besides removing toxic heme, produces biliverdin, iron ions and carbon monoxide. (springer.com)
  • Fusion proteins , also known as chimeric proteins , are proteins created through the joining of two or more genes which originally coded for separate proteins. (chemeurope.com)
  • Chimeric mutant proteins occur natually when a large-scale mutation , typically a chromosomal translocation, creates a novel coding sequence containing parts of the coding sequences from two different genes. (chemeurope.com)
  • Naturally occurring fusion genes are most commonly created when a chromosomal translocation replaces the terminal exons of one gene with intact exons from a second gene. (chemeurope.com)
  • Many important cancer-promoting oncogenes are fusion genes produced in this way. (chemeurope.com)
  • Non-receptor tyrosine kinases encoded by the C-ABL GENES. (jefferson.edu)
  • BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia. (jefferson.edu)
  • Also new antibody clones against rigorously selected epitopes of proteins involved in chromosomal translocations were developed for detection of most frequent fusion proteins in acute leukemia and chronic myeloid leukemia. (wikipedia.org)
  • Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become standard first-line therapy for patients with chronic myeloid leukemia (CML), but the frequency of resistance increases in advancing stages of disease. (lu.se)
  • Chronic myeloid leukemia (CML) results from BCR-ABL oncogene, which blocks CML cells differentiation and protects these cells from apoptosis. (jcancer.org)
  • Chronic myeloid leukemia (CML) is a clonal expansion of the progenitor hematopoietic stem cells arising from the existence of the fusion BCR-ABL oncogene, that represents 15%-20% of the newly diagnosed cases of leukemia patients [ 1 - 2 ]. (jcancer.org)
  • Chronic myeloid leukemia (CML) is a myeloproliferative disease caused due to translocation between chromosome 9 and 22 leading to a chimeric gene product known as Bcr-Abl. (eurekaselect.com)
  • On the other hand about 30% of patients with Ph+ ALL harbor the M-BCR p210or p210[5,6,7]. (bios-mep.info)
  • BCR-ABL oncogene encodes a BCR-ABL tyrosine kinase (TK), which triggers different downstream targets including c-Myc, STAT5 and CrkL, which participated in the control of cell differentiation, proliferation, migration and other cellular behaviors [ 3 - 5 ]. (jcancer.org)
  • The derivative chromosome BIBR 953 22 is the so called Philadelphia chromosome (Ph) which encodes the BCR/ABL kinase. (bios-mep.info)
  • The fusion gene on der9 differs between m-BCR-p185and M-BCR-p210gene encodes a small ABL/BCR with an approximate molecular mass of 40 kDa (p40transcript is detectable in 65% of the CML patients [15] and the p96transcript is present in 100% of examined patients with m-BCR Ph+ ALL [16]. (bios-mep.info)
  • This gene encodes a protein containing a C3HC4-type RING finger domain, which is a specialized type of Zn-finger that binds two atoms of zinc and is thought to be involved in mediating protein-protein interactions. (cancerindex.org)
  • In models of Ph+ ALL we show that the functional interplay between ABL/BCR and BCR/ABL not only increases the transformation potential of BCR/ABL but is also indispensable for the growth and survival of Ph+ ALL leukemic cells. (bios-mep.info)
  • Such CTL recognize HLA-matched, BCR-ABL-positive leukemic cells, implying efficient natural processing and presentation of these junctional peptides. (pasteur.fr)
  • T315I mutated BCR-ABL is the main cause of the resistance mediated by imatinib and second generation BCR-ABL inhibitor. (jcancer.org)
  • Here, we determined the effect of Jiyuan oridonin A (JOA), an ent -kaurene diterpenoid compound, on the differentiation blockade in imatinib-sensitive, particularly, imatinib-resistant CML cells with BCR-ABL-T315I mutation by cell proliferation assay, apoptosis analysis, cell differentiation analysis, cell cycle analysis and colony formation assay. (jcancer.org)
  • Therefore, imatinib was a paradigm of targeted therapies, which due to that imatinib inhibits the phosphorylation of BCR-ABL then suppress the activation of BCR-ABL tyrosine kinase [ 6 ]. (jcancer.org)
  • Targeting BCR/ABL by selective ATP competitors, such as imatinib or nilotinib, is a well validated therapeutic concept, but unable to definitively eradicate the disease. (bios-mep.info)
  • The Bcr-Abl point mutations, including the gatekeeper T315I mutations, are the principal cause for the development of resistance to TKIs. (eurekaselect.com)
  • Scope includes mutations and abnormal protein expression. (cancerindex.org)
  • The abnormal BCR-ABL1 gene is formed when pieces of chromosomes 9 and 22 break off and trade places. (medlineplus.gov)
  • These drugs work by blocking an abnormal protein formed when parts of chromosomes 9 and 22 switch places. (dana-farber.org)
  • Human chronic myelogenous leukemia (CML) is characterized by a translocation between chromosomes 9 and 22 that results in a BCR-ABL fusion gene coding for chimeric proteins. (pasteur.fr)
  • Chimeric proteins can also be manufactured with toxins or anti-bodies attached to them in order to study disease development. (chemeurope.com)
  • Several drugs made from chimeric proteins are currently available for medical use. (chemeurope.com)
  • Nrf2 consists of six functional Neh domains (Neh1-Neh6), from which, the amino-terminal Neh2 domain controls binding Keap1-the inhibitor protein Kelch-like ECH-associated protein 1, that is responsible for the cytosolic sequestration of Nrf2 under physiological conditions (Fig. 2 a). (springer.com)
  • The bcr-abl fusion protein is a well-known example of an oncogenic fusion protein, and is considered to be the primary oncogenic driver of chronic myelogenous leukemia. (chemeurope.com)
  • Through the fusion to BCR, ABL constitutively activates its down-stream signaling pathways, including RAS, JAK/STAT and PI-3 kinase [1,12]. (bios-mep.info)
  • Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. (jefferson.edu)
  • Elimination of BCR/ABL-dependent intracellular signals triggers apoptosis, but it is unclear whether this activates additional cell survival and/or death pathways. (lu.se)
  • Our previous study has shown that CCAAT-enhancer binding protein β (C/EBPβ) is an important regulator in METH-induced neuronal autophagy and apoptosis. (cancerindex.org)
  • Most importantly, S-20-induced autophagy activates the ERK pathway and then inhibits the expression of drug resistance protein, which is the main reason to overcome K562/ADR resistance, rather than apoptosis. (bvsalud.org)
  • Mechanistically, the cell differentiation mediated by JOA may be originated from the inhibition of BCR-ABL/c-MYC signaling in CML cells expressing wild-type BCR-ABL and BCR-ABL-T315I. (jcancer.org)
  • Binding mode and structural elements of Bcr-Abl inhibition are discussed with emphasis on pathways involved in this complex disease to determine alternative strategies and combination therapies. (eurekaselect.com)
  • The mutant proteins often retain some of their capabilities but are no longer sensitive to the controls that regulate the normal form of the protein. (cancerquest.org)
  • We found that JOA at lower concentration significantly inhibited the proliferation of CML cells expressing mutant BCR-ABL (T315I mutation included) and wild-type BCR-ABL, which was due to that JOA induced the cell differentiation and the cell cycle arrest at G0/G1 phase. (jcancer.org)
  • We have shown here that IM induces autophagy in CML blast crisis cell lines, CML primary cells, and p210BCR/ABL-expressing myeloid precursor cells. (lu.se)
  • In fact M-BCR p210is associated with primarily myeloid leukemia. (bios-mep.info)
  • c-Abl plays a role in normal HEMATOPOIESIS especially of the myeloid lineage. (jefferson.edu)
  • Native BCR acts as a negative regulator of proliferation and oncogenic transformation by a down-regulation of RAS-mediated signaling [18]. (bios-mep.info)
  • Oncogenic transformation of c-abl arises when specific N-terminal amino acids are deleted, releasing the kinase from negative regulation. (jefferson.edu)
  • Protein enzymes are chains of amino acids and when a phosphoryl group, PO32−, is covalently attached to one of the amino acids, it changes the three-dimensional configuration and function of the protein. (callaix.com)
  • IM-induced autophagy did not involve c-Abl or Bcl-2 activity but was associated with ER stress and was suppressed by depletion of intracellular Ca2+, suggesting it is mechanistically. (lu.se)
  • What is a BCR-ABL1 genetic test? (medlineplus.gov)
  • A BCR-ABL1 genetic test uses a sample of blood or bone marrow to look for an abnormal gene called BCR-ABL1 . (medlineplus.gov)
  • There are different types of BCR-ABL1 genetic tests. (medlineplus.gov)
  • An abnormal BCR-ABL1 gene is an acquired genetic change. (medlineplus.gov)
  • Why do I need a BCR-ABL1 genetic test? (medlineplus.gov)
  • If your health care provider thinks you may have a type of leukemia that involves the BCR-ABL1 gene , you may need a BCR-ABL1 genetic test to make a diagnosis. (medlineplus.gov)
  • A recombinant fusion protein is a protein created through genetic engineering of a fusion gene. (chemeurope.com)
  • Discontinuation of therapy is attractive to both patients and physicians because maintaining a stable BCR-ABL transcript level without therapy would imply true operational CML cure. (mcmaster.ca)
  • What pathways are this gene/protein implicaed in? (cancerindex.org)
  • The PI3K/Akt/mTOR signaling pathway is a key regulator of diverse physiological functions such as proliferation, global protein, and lipid synthesis as well as many metabolic pathways interacting to increase secretory capabilities. (go.jp)
  • Recent studies utilizing immunohistochemistry evaluation of ordinary and tumor tissue unveiled that Kaiso protein is predominantly localized inside the cytoplasm in the cell or is totally absent, though. (screeninglibraries.com)
  • It has been suggested that Recombinant fusion proteins, Chimera (protein) be merged into this article or section. (chemeurope.com)
  • Recombinant fusion proteins are be created artificially by recombinant DNA technology for use in biological research or therapeutics. (chemeurope.com)
  • Electrophoresis mobility shift assay of the RUNX1 consensus sequence of the TRAIL promoter with recombinant RUNX1 and CBFß proteins was also performed. (bvsalud.org)
  • Exogenous treatment of recombinant TRAIL proteins was found to induce leukemia cell death. (bvsalud.org)
  • But the abnormal BCR-ABL1 gene has instructions for an abnormal protein. (medlineplus.gov)
  • The junctional region of the BCR-ABLb3a2 molecule represents a potential leukemia-specific antigen which could be recognized by cytotoxic T lymphocytes (CTL). (pasteur.fr)
  • [6] SNPs may be synonymous with no change in amino acid or nonsynonymous resulting in amino acid substitution causing alteration in the protein molecule. (brjnmims.org)
  • For instance, how can cells control the diverse patterns of glycosylation of various secretory proteins in the endoplasmic reticulum and Golgi in an orderly manner with high accuracy? (go.jp)
  • Both technologies have been primarily focused on measurement of protein epitopes, but have been used to measure nucleic acids such as targeted mRNA 11 , 12 . (nature.com)
  • Two principal breaks occur in the (breakpoint cluster region) gene locus on chromosome 22: the (major) M-BCR, between exons 12 and 16, and the (minor) m-BCR, in the first intron of and m-BCR to that of p185(Abelson tyrosin protein kinase 1) gene on chromosome 9 falls within the intron between the exons 1 and 2. (bios-mep.info)
  • In other words, the linear portion of a polypeptide which corresponds to a given domain, such as a tyrosine kinase domain, may be removed from the rest of the protein without destroying its intrinsic enzymatic capability. (chemeurope.com)
  • We present a method enabling simultaneous, ultra-high throughput single-cell barcoding of millions of cells for targeted analysis of proteins and RNAs. (nature.com)
  • The protein causes certain bone marrow cells to make large numbers of abnormal white blood cells. (medlineplus.gov)
  • Today, patients generally have the option to stop TKI treatment if they have been taking the drug for three years and have had no evidence of the DNA for BCR-ABL for two years -- that is, an ultra-sensitive PCR test detects no cancer cells in their blood. (dana-farber.org)
  • We also measured the levels of phosphorylated tuberous sclerosis complex 2 (TSC2) protein and Parkin protein level in SH-SY5Y cells. (cancerindex.org)
  • Furthermore, TRAIL expression was reduced in leukemia cells carrying the t(8;21) translocation, where the RUNX1-ETO chimeric protein interfere with normal RUNX1 function. (bvsalud.org)
  • Proteins are constantly being phosphorylated and dephosphorylated in living cells. (callaix.com)
  • Fusion Proteins, bcr-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (jefferson.edu)
  • Keap1 is a cysteine-rich protein, known to be anchored to actin cytoskeleton [ 5 ], serving as an adaptor protein for the Cul3-dependent E3 ubiquitin ligase complex. (springer.com)
  • Oxidative stress generated during such stressful conditions may damage DNA and proteins, and as a consequence the cellular processes are disturbed. (springer.com)
  • Ribosomal protein S3 is a protein component of the ribosome, which is a cellular structure that plays a central role in protein synthesis. (bmbreports.org)
  • When the cellular action(s) is completed, the phosphate group is removed and that protein is "turned off. (callaix.com)
  • BCR harbors both RHO-GEF and RAC-GAP functions and controls cytoskeleton modeling by regulating the activity of RHO-like GTPases [17,20]. (bios-mep.info)
  • Ribosomal protein S3 (RpS3) is involved in protein biosynthesis as a component of the ribosome complex and possesses endonuclease activity to repair damaged DNA. (bmbreports.org)
  • The protein also contains an AAA domain, which is associated with ATPase activity. (cancerindex.org)
  • The functionality of fusion proteins is made possible by the fact that many protein functional domains are modular . (chemeurope.com)
  • This creates a single gene which can be transcribed , spliced , and translated to produce a functional fusion protein. (chemeurope.com)
  • That DNA sequence will then be expressed by a cell as a single protein. (chemeurope.com)
  • The presence of ABL/BCR changed the phenotype of the leukemia most likely due to its capacity CR2 to influence the stem cell population as shown by our data. (bios-mep.info)
  • The inhibitory effect of BCR/ABL on the B-cell signaling is counteracted by the ABL/BCRs, the reciprocal t(9;22) fusion proteins [13]. (bios-mep.info)
  • An in vitro immunocomplex kinase assay indicated that the rpS3 protein acts as a substrate for Lyn, which phosphorylates the Y167 residue of rpS3. (bmbreports.org)